Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ)
Hefei, CN
Hefei Lifeon Pharmaceutical Co., Ltd. specializes in the research, development, production, and distribution of a wide array of pharmaceutical goods. Its product portfolio encompasses active pharmaceutical ingredients (APIs) such as succimer, urea, paeonol, felodipine, doxazosin mesylate, zofenopril calcium, troxerutin, and sodium 2,3-dimercapto-1-propanesulfonate. The company also manufactures various medicinal preparations, including felodipine sustained-release tablets, doxazosin mesylate extended-release tablets, melbinum glipizide tablets, yiqihewei capsules, kunning granules, armillariella oral solution, paeonol ointment, urea and vitamin E cream, Kecuo Yintong gel, and Compound Golden Larch bark gel. Additionally, Hefei Lifeon Pharmaceutical supplies plant extracts like clove oil, evening primrose oil, herba clinopodii P.E, quercetin, and dihydroquercetin. Beyond its manufacturing operations, the company operates a retail chain for pharmaceuticals. Established in 2002, Hefei Lifeon Pharmaceutical Co., Ltd. is headquartered in Hefei, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.04% | -4.51% | -13.52% | -22.54% | -29.09% | -23.50% | -17.66% | -41.78% | -34.60% | +20.53% | +409.26% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+2.3% ★ Q1'26: -0.9% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+3.6% Q1'26: -5.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+8.5% ★ Q1'26: +9.4% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+11.9% ★ Q1'26: +11.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+10.6% ★ Q1'26: +9.1% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.7% ★ Q1'26: -2.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.22× ★ Q1'26: 0.42× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
2.61B
est.
|
1.90B
est: 3.19B (-40.4%)
|
2.58B
est: 3.19B (-19.2%)
|
1.52B
est: 1.47B (+3.2%)
|
1.55B
est: 1.85B (-16.1%)
|
2.29B
2.29B – 2.29B
+23.7% YoY
|
2.74B
2.74B – 2.74B
+19.4% YoY
|
| EBITDA |
331.23M
est.
|
294.53M
est: 405.12M (-27.3%)
|
266.65M
est: 405.12M (-34.2%)
|
248.72M
est: 186.75M (+33.2%)
|
274.62M
est: 235.25M (+16.7%)
|
291.11M
291.11M – 291.11M
+23.7% YoY
|
347.48M
347.48M – 347.48M
+19.4% YoY
|
| EBIT |
268.45M
est.
|
258.82M
est: 328.33M (-21.2%)
|
240.71M
est: 328.33M (-26.7%)
|
173.82M
est: 151.36M (+14.8%)
|
184.14M
est: 190.66M (-3.4%)
|
235.93M
235.93M – 235.93M
+23.7% YoY
|
281.62M
281.62M – 281.62M
+19.4% YoY
|
| Net Income |
266.19M
est.
|
226.67M
est: 324.77M (-30.2%)
|
209.25M
est: 324.77M (-35.6%)
|
160.60M
est: 286.78M (-44.0%)
|
165.19M
est: 195.01M (-15.3%)
|
233.25M
233.25M – 233.25M
+19.6% YoY
|
298.25M
298.25M – 298.25M
+27.9% YoY
|
| SGA |
750.67M
est.
|
651.44M
est: 918.13M (-29.0%)
|
665.29M
est: 918.13M (-27.5%)
|
764.67M
est: 423.24M (+80.7%)
|
590.06M
est: 533.15M (+10.7%)
|
659.75M
659.75M – 659.75M
+23.7% YoY
|
787.50M
787.50M – 787.50M
+19.4% YoY
|
| EPS |
1.39
est.
|
1.18
est: 1.70 (-30.5%)
|
1.11
est: 1.70 (-34.7%)
|
0.84
est: 1.50 (-44.0%)
|
0.87
est: 1.02 (-14.7%)
|
1.22
1.22 – 1.22
+19.6% YoY
|
1.56
1.56 – 1.56
+27.9% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Huanxi Cui | General Manager | — | male |
| Jun Chen | R&D Director & Non-Independent Director | — | male |
| Jun Xia | Deputy GM & Secretary of the Board | — | male |
| Qing Wang | Deputy GM & Non-Independent Director | — | female |
| Shaobing Gou | Financial Director | — | male |
| Tianhe Dai | Deputy General Manager | — | male |
| Xue Chen He | Accounting Supervisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 003020.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
